scispace - formally typeset
S

Suash Sharma

Researcher at Georgia Regents University

Publications -  51
Citations -  1892

Suash Sharma is an academic researcher from Georgia Regents University. The author has contributed to research in topics: Differential diagnosis & Cancer. The author has an hindex of 17, co-authored 49 publications receiving 1631 citations. Previous affiliations of Suash Sharma include All India Institute of Medical Sciences.

Papers
More filters
Journal ArticleDOI

Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis

TL;DR: The objective of this review is to critically evaluate the major mechanisms underlying stroke pathophysiology, with emphasis on potential novel targets for designing newer therapeutic modalities.
Journal ArticleDOI

Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis.

TL;DR: A judicious combination of quantitative and qualitative microscopic angiogenic parameters, with emphasis on neoangiogenesis and vascular patterns wherever applicable, should be an integral component of a more consistent tumour staging system for accurate prognostic evaluation of tumours, selection of optimal anti‐angiogenic therapy and pertinent research.
Journal ArticleDOI

Neurocytoma: a comprehensive review.

TL;DR: E Epidemiology, histogenesis, clinical profile, histology, neuroimaging and therapeutic modalities of neurocytomas have been comprehensively reviewed, with special emphasis on CN and extraventricular neurocyTomas and their atypical counterparts.
Journal ArticleDOI

Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth

TL;DR: It is suggested that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.